MASK-air Data Viewer screenshot


Conseil Regional Languedoc Roussillon © MACVIA-LR.


Allergic rhinitis is among the most common diseases in the world and affects 20% of the Australian population. It exists in all age groups, often starts early in life and persists across the life cycle. Allergic rhinitis often impairs social life, work and school performance.

Peercode colleagues Michiel van Eerd and Govert de Vries are co-authors of 5 international peer-reviewed scientific articles that have been published by the MACVIA ARIA consortium (an asthma and Rhinitis NGO).


The MASK-air by MACVIA-ARIA enables the user to keep a daily record of allergic rhinitis (also known as hay fever) and asthma symptoms and medication use. The app is simple to use, and combines practicality with good scientific practice, having been developed with a global team of world leading allergy clinicians.
Tracking the daily symptoms and medication use allows the user to see how well the treatment is working, identify any patterns in the symptoms and therefore take control of the disease, and improve communication with a doctor or pharmacist.

MASK-air App on mobile device

The results are shown in easy to read graphs, allowing to view the symptom experience over time, in days, months, or years.

The diary has an optional reminder function to help the user remember to track and treat the symptoms, allowing to set a reminder every day, twice a day or once per week. If the user record symptoms that suggest the allergic rhinitis is uncontrolled for 3 days in a row or more, the diary will alert to this fact in case you would like to share your results with your doctor or pharmacist.
The diary also includes a geo localisation function that, in the future, will permit the app to allow the user to compare the level of symptom control with other allergy sufferers in an area, or alert the user if an allergy has reported suffering from will soon be arriving in an area!

The MASK-air App is available in 24 languages for iOS and Android.

See also the publication "Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - Reference Site Twinning (EIP on AHA)".